Early Change in the Plasma Levels of Circulating Soluble Immune Checkpoint Proteins in Patients with Unresectable Hepatocellular Carcinoma Treated by Lenvatinib or Transcatheter Arterial Chemoembolization

Immune checkpoint inhibitors, combined with anti-angiogenic agents or locoregional treatments (e.g., transarterial chemoembolization (TACE)), are expected to become standard-of-care for unresectable hepatocellular carcinoma (HCC). We measured the plasma levels of 16 soluble checkpoint proteins using...

Descripción completa

Detalles Bibliográficos
Autores principales: Odagiri, Naoshi, Hai, Hoang, Thuy, Le Thi Thanh, Dong, Minh Phuong, Suoh, Maito, Kotani, Kohei, Hagihara, Atsushi, Uchida-Kobayashi, Sawako, Tamori, Akihiro, Enomoto, Masaru, Kawada, Norifumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464181/
https://www.ncbi.nlm.nih.gov/pubmed/32722224
http://dx.doi.org/10.3390/cancers12082045

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464181/
https://www.ncbi.nlm.nih.gov/pubmed/32722224
http://dx.doi.org/10.3390/cancers12082045

Ejemplares similares